299 320
[4]
Bourke L, Smith D, Steed L, et al. Exercise for men with prostate cancer: a systematic review and meta-analysis. Eur Urol 2016;69:693–703.[5]
Galvao DA, Taaffe DR, Spry N, Joseph D, Newton RU. Combined resistance and aerobic exercise program reverses muscle loss in men undergoing androgen suppression therapy for prostate cancer without bone metastases: a randomized controlled trial. J Clin Oncol 2010;28:340–7.
[6]
Cormie P, Galvao DA, Spry N, et al. Can supervised exercise prevent treatment toxicity in patients with prostate cancer initiating an- drogen-deprivation therapy: a randomised controlled trial. BJU Int 2015;115:256–66.[7]
Segal RJ, Reid RD, Courneya KS, et al. Resistance exercise in men receiving androgen deprivation therapy for prostate cancer. J Clin Oncol 2003;21:1653–9.
[8]
Segal RJ, Reid RD, Courneya KS, et al. Randomized controlled trial of resistance or aerobic exercise inmen receiving radiation therapy for prostate cancer. J Clin Oncol 2009;27:344–51.
[9]
Bourke L, Gilbert S, Hooper R, et al. Lifestyle changes for improving disease-specific quality of life in sedentary men on long-term androgen-deprivation therapy for advanced prostate cancer: a randomised controlled trial. Eur Urol 2014;65:865–72.
[10]
Bourke L, Doll H, Crank H, Daley A, Rosario D, Saxton JM. Lifestyle intervention in men with advanced prostate cancer receiving an- drogen suppression therapy: a feasibility study. Cancer Epidemiol Biomarkers Prev 2011;20:647–57.[11]
Newton RU, Taaffe DR, Spry N, et al. A phase III clinical trial of exercise modalities on treatment side-effects in men receiving therapy for prostate cancer. BMC Cancer 2009;9:210.[12]
Galvao DA, Spry N, Denham J, et al. A multicentre year-long randomised controlled trial of exercise training targeting physical functioning in men with prostate cancer previously treated with androgen suppression and radiation from TROG 03.04 RADAR. Eur Urol 2014;65:856–64.
[13]
Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organi- zation for Research and Treatment of Cancer QLQ-C30: a quality-of- life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365–76.[14]
Ware Jr JE, Sherbourne CD, The MOS. 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473–83.[15]
Ware Jr JE, Kosinski M, Bjorner JB, Turner-Bowker DM, Gandek B, Maruish ME. User’s Manual for the SF-36v2 Health Survey. ed. 2 Rhode Island: QualityMetric Incorporated; 2008.[16]
Newman AB, Simonsick EM, Naydeck BL, et al. Association of long- distance corridor walk performance with mortality, cardiovascular disease, mobility limitation, and disability. JAMA 2006;295: 2018–26.[17]
Taaffe DR, Duret C, Wheeler S, Marcus R. Once-weekly resistance exercise improves muscle strength and neuromuscular perfor- mance in older adults. J Am Geriatr Soc 1999;47:1208–14.[18]
Vellas B, Guigoz Y, Garry PJ, et al. The Mini Nutritional Assessment (MNA) and its use in grading the nutritional state of elderly patients. Nutrition 1999;15:116–22.
[19]
Godin G, Shephard RJ. A simple method to assess exercise behavior in the community. Can J Appl Sport Sci 1985;10:141–6.
[20]
Nordin A, Taft C, Lundgren-Nilsson A, Dencker A. Minimal impor- tant differences for fatigue patient reported outcome measures-a systematic review. BMC Med Res Methodol 2016;16:62.[21]
Thabane L, Mbuagbaw L, Zhang S, et al. A tutorial on sensitivity analyses in clinical trials: the what, why, when and how. BMC Med Res Methodol 2013;13:92.
[22]
Gavin AT, Drummond FJ, Donnelly C, O’Leary E, Sharp L, Kinnear HR. Patient-reported ‘‘ever had’’ and ‘‘current’’ long-term physical symptoms after prostate cancer treatments. BJU Int 2015;116: 397–406.[23]
Scott NW, Fayers PM, Aaronson NK, et al. EORTC QLQ-C30 reference values. Brussels, Belgium: EORTC Quality of Life Group; 2008.[24]
Potosky AL, Reeve BB, Clegg LX, et al. Quality of life following localized prostate cancer treated initially with androgen depriva- tion therapy or no therapy. J Natl Cancer Inst 2002;94:430–7.[25]
Alibhai SM, Breunis H, Timilshina N, et al. Impact of androgen- deprivation therapy on physical function and quality of life in men with nonmetastatic prostate cancer. J Clin Oncol 2010;28:5038–45.
[26]
Bjorner JB, Wallenstein GV, Martin MC, et al. Interpreting score differences in the SF-36 Vitality scale: using clinical conditions and functional outcomes to define the minimally important difference. Curr Med Res Opin 2007;23:731–9.[27]
Galva˜o DA, Newton RU, Gardiner RA, et al. Compliance to exercise- oncology guidelines in prostate cancer survivors and associations with psychological distress, unmet supportive care needs, and quality of life. Psycho-Oncology 2015;24:1241–9.[28]
Simonsick EM, Fan E, Fleg JL. Estimating cardiorespiratory fitness in well-functioning older adults: treadmill validation of the long distance corridor walk. J Am Geriatr Soc 2006;54:127–32.[29]
Minton O, Stone P. A systematic review of the scales used for the measurement of cancer-related fatigue (CRF). Ann Oncol 2009;20:17–25.E U R O P E A N U R O L O G Y 7 2 ( 2 0 1 7 ) 2 9 3 – 2 9 9
299